A Phase Ib/II Study of SHR-A1811 and Fulvestrant in Combination With or Without HS-10352 in Locally Advanced or Metastatic Breast Cancer Patients Who Progressed After Adjuvant Therapy
Latest Information Update: 29 Jan 2025
Price :
$35 *
At a glance
- Drugs Fulvestrant (Primary) ; HS-10352 (Primary) ; Trastuzumab rezetecan (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 29 Jan 2025 New trial record